Alvotech to Report First Quarter 2026 Financial Results on May 6
Biotechnology firm Alvotech announced it will release its first quarter 2026 financial results after market close on May 6. The company will also host a webcast with a live Q&A session on May 7.
Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines, will announce its financial results for the first quarter of 2026 after the U.S. market close on Wednesday, May 6, 2026. The company made the announcement on Friday, April 24.
The Reykjavik-based firm focuses on delivering high-quality, cost-effective biosimilar products worldwide. Alvotech operates with a fully integrated approach and extensive in-house capabilities to support its development pipeline.
Following the earnings release, Alvotech will host a webcast with a live question-and-answer session on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST). Presentation materials will be made available on the company's investor website prior to the call.
Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company has established commercial partnerships to ensure global reach in key markets.